Drug intelligence / Profile preview

Wontran ER

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

Wontran ER, also known by its code name DW-0919, is an extended-release fixed-dose combination drug containing tramadol and acetaminophen. It is indicated for the treatment of moderate to severe chronic pain that is not responsive to non-opioid analgesics. Tramadol acts as a weak mu-opioid receptor agonist and inhibits the reuptake of serotonin and norepinephrine, while acetaminophen's mechanism involves inhibition of cyclooxygenase enzymes in the central nervous system and modulation of the endocannabinoid and serotonergic systems.

Brand names: Wontran ER
Other names: Wontran ER Tab保寧緩釋錠

Targets

SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)NET (Norepinephrine Transporter)COX

Beyond the preview

Go deeper on Wontran ER.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wontran ER.

Explore the full profile